|
|
SFX by Ex Libris Inc.
|
List of services to meet your request
|
||||||||
|
||||||||
© 2024 SFX by Ex Libris Inc. | Cookie Policy
CrossRef Omogočeno
![](https://beacon01.alma.exlibrisgroup.com/boom/apache_pb.gif?SRVR=adz.izum.si&IP=193.2.126.232&A=SFX&P=SFXMenu&S=s0408925C-5F32-11EF-ABB2-25BA84CE164B&I=39IZM&T=&OP=Display&O=html&O1=15724265&O2=4100000011247204&O3=&O4=summon.serialssolutions.com&O5=https%3A%2F%2Fadz.izum.si%2Fsfxlcl41%3Fctx_enc%3Dinfo%253Aofi%252Fenc%253AUTF-8%26ctx_ver%3DZ39.88-2004%26rfr_id%3Dinfo%253Asid%252Fsummon.serialssolutions.com%26rft.atitle%3DImmune%2520signatures%2520predict%2520development%2520of%2520autoimmune%2520toxicity%2520in%2520patients%2520with%2520cancer%2520treated%2520with%2520immune%2520checkpoint%2520inhibitors%26rft.au%3DBerner%252C%2520Fiamma%26rft.au%3DFriebel%252C%2520Ekaterina%26rft.au%3DNu%25C3%25B1ez%252C%2520Nicolas%2520Gonzalo%26rft.au%3DUnger%252C%2520Susanne%26rft.date%3D2023-02-10%26rft.eissn%3D2666-6340%26rft.epage%3D129.e7%26rft.externalDocID%3DS2666634022005232%26rft.genre%3Darticle%26rft.issn%3D2666-6340%26rft.issue%3D2%26rft.jtitle%3DMed%2520%2528New%2520York%252C%2520N.Y.%2520%253A%2520Online%2529%26rft.pub%3DElsevier%2520Inc%26rft.spage%3D113%26rft.volume%3D4%26rft_id%3Dinfo%253Adoi%252F10.1016%252Fj.medj.2022.12.007%26rft_val_fmt%3Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal&O6=1-ELSEVIER_SCIENCEDIRECT_AUTOLOAD_JOURNALS-getFullTxt-object,2-UNPAYWALL-getFullTxt-object,3-DOI-getDOI-object,4-COBIB_SI_LCL-getHolding-object,5-REFWORKS_EXPORT_TOOL-getReference-object,6-GOOGLE_SCHOLAR_FREE-getWebSearch-object,7-WWW_SEARCH_ENGINES_FREE-getWebSearch-object&O7=1.041581&O8=N&O9=<ctx:context-object identifier="urn:sfxstat:15724265-s0408925C-5F32-11EF-ABB2-25BA84CE164B" timestamp="2024-08-20T22:23:10Z" xmlns:ctx="info:ofi/fmt:xml:xsd:ctx">
<ctx:referent>
<ctx:identifier>urn:sfxid:4100000011247204</ctx:identifier>
<ctx:metadata-by-val>
<ctx:format>info:ofi/fmt:xml:xsd:journal</ctx:format>
<ctx:metadata>
<jnl:journal xmlns:jnl="info:ofi/fmt:xml:xsd:journal">
<jnl:atitle>Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors</jnl:atitle>
<jnl:jtitle>Med</jnl:jtitle>
<jnl:date>2023-02-10</jnl:date>
<jnl:spage>113</jnl:spage>
<jnl:epage>129.e7</jnl:epage>
<jnl:issn>2666-6340</jnl:issn>
<jnl:volume>4</jnl:volume>
<jnl:issue>2</jnl:issue>
<jnl:genre>article</jnl:genre>
<jnl:eissn>2666-6340</jnl:eissn>
<jnl:language>eng</jnl:language>
<jnl:authors></jnl:authors>
</jnl:journal>
</ctx:metadata>
</ctx:metadata-by-val>
</ctx:referent>
<ctx:requester>
<ctx:identifier>urn:ip:6c8d3f9f162a972b8c7dc36a62d467f46feecdc4</ctx:identifier>
<ctx:identifier>urn:UUID:s0408925C-5F32-11EF-ABB2-25BA84CE164B</ctx:identifier>
</ctx:requester>
<ctx:referrer>
<ctx:identifier>info:sid/summon.serialssolutions.com</ctx:identifier>
</ctx:referrer>
<ctx:service-type>
<ctx:metadata-by-val>
<ctx:format>info:ofi/fmt:xml:xsd:svcList</ctx:format>
<ctx:metadata>
<svc:svcList xmlns:svc="http://www.exlibrisgroup.com/schema/info:ofi/fmt:xml:xsd:sch_svc"></svc:svcList>
</ctx:metadata>
</ctx:metadata-by-val>
</ctx:service-type>
<ctx:resolver>
<ctx:identifier>https://adz.izum.si/sfxlcl41</ctx:identifier>
</ctx:resolver>
</ctx:context-object>
&)